Head to Head Review: Tiziana Life Sciences (NASDAQ:TLSA) vs. MacroGenics (NASDAQ:MGNX)

MacroGenics (NASDAQ:MGNX) and Tiziana Life Sciences (NASDAQ:TLSA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, earnings, profitability, institutional ownership, dividends and valuation.

Earnings and Valuation

This table compares MacroGenics and Tiziana Life Sciences”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MacroGenics	$148.34 million	0.67	-$9.06 million	($0.89)	-1.78
Tiziana Life Sciences	N/A	N/A	-$17.69 million	N/A	N/A

MacroGenics has higher revenue and earnings than Tiziana Life Sciences.

Profitability

This table compares MacroGenics and Tiziana Life Sciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
MacroGenics	-69.07%	-89.42%	-38.57%
Tiziana Life Sciences	N/A	N/A	N/A

Analyst Ratings

This is a summary of current ratings and recommmendations for MacroGenics and Tiziana Life Sciences, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MacroGenics	0	7	2	1	2.40
Tiziana Life Sciences	0	0	0	0	0.00

MacroGenics presently has a consensus price target of $6.38, indicating a potential upside of 303.48%. Given MacroGenics’ stronger consensus rating and higher possible upside, equities analysts plainly believe MacroGenics is more favorable than Tiziana Life Sciences.

Insider & Institutional Ownership

96.9% of MacroGenics shares are held by institutional investors. 13.0% of MacroGenics shares are held by company insiders. Comparatively, 39.8% of Tiziana Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Risk and Volatility

MacroGenics has a beta of 2.2, suggesting that its stock price is 120% more volatile than the S&P 500. Comparatively, Tiziana Life Sciences has a beta of 0.29, suggesting that its stock price is 71% less volatile than the S&P 500.

Summary

MacroGenics beats Tiziana Life Sciences on 8 of the 12 factors compared between the two stocks.

About MacroGenics

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.

About Tiziana Life Sciences

Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti- receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.Kingdom.